文献速递白血病造血干细胞移植与细胞治疗

影响CD19 CAR T细胞治疗后复发免疫表型的输注前因素

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.
PubMed 文献 · Blood Adv · 2023-01-01

该多中心回顾性研究分析了420例接受鼠源CD19 CAR T细胞治疗的复发/难治B细胞急性淋巴细胞白血病儿童和年轻成人,166例(39.5%)复发,其中CD19阳性复发83例(50%)、CD19阴性复发68例(41%)、谱系转换12例(7.2%)。既往完全缓解累积次数多与CD19阳性复发相关,高输注前疾病负荷、blinatumomab无应答、年龄较大和4-1BB CAR构建体与CD19阴性复发相关,KMT2A重排是唯一与谱系转换相关的输注前危险因素。CAR后复发的中位总生存为11.9个月(95%CI,9-17),谱系转换者无长期生存者。

要点

  • 420例接受CD19 CAR T细胞治疗者中166例(39.5%)复发,CD19阳性复发占50%、CD19阴性复发占41%、谱系转换占7.2%。
  • 既往完全缓解累积次数多与CD19阳性复发相关;高输注前疾病负荷、blinatumomab无应答、年龄较大和4-1BB CAR构建体与CD19阴性复发相关。
  • KMT2A重排是唯一与谱系转换相关的输注前危险因素;CAR后复发中位总生存11.9个月(95%CI,9-17),谱系转换者无长期生存者。

核心结论

  • CAR后复发患者结局差,中位总生存11.9个月(95%CI,9-17),谱系转换者无长期生存者。
  • 鉴于CAR后复发结局差,研究复发预防策略(如巩固性造血干细胞移植)至关重要,值得在前瞻性临床试验中进一步研究。

研究设计与样本

  • 多中心回顾性综述,纳入接受鼠源CD19 CAR构建体治疗的复发/难治B细胞急性淋巴细胞白血病儿童和年轻成人。
  • 共420例接受CAR治疗,其中166例(39.5%)复发。

主要发现

  • 166例复发者中,CD19阳性复发83例(50%)、CD19阴性复发68例(41%)、谱系转换12例(7.2%)。
  • 既往完全缓解累积次数较多与CD19阳性复发相关。
  • 高输注前疾病负荷、既往blinatumomab无应答、年龄较大和4-1BB CAR构建体与CD19阴性复发相关。
  • KMT2A重排是唯一与谱系转换相关的输注前危险因素。
  • CAR后复发后中位总生存为11.9个月(95%CI,9-17),谱系转换患者无长期生存者。

临床怎么用

  • 作者认为,鉴于CAR后复发结局差,研究复发预防策略(如巩固性造血干细胞移植)至关重要,值得在前瞻性临床试验中进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse following chimeric antigen receptor (CAR) T-cell therapy directed against CD19 for relapsed/refractory B-acute lymphoblastic leukemia (r/r B-ALL) remains a significant challenge. Three main patterns of relapse predominate: CD19 positive (CD19pos) relapse, CD19 negative (CD19neg) relapse, and lineage switch (LS). Development and validation of risk factors that predict relapse phenotype could help define potential pre- or post-CAR T-cell infusion interventions aimed at decreasing relapse. Our group sought to extensively characterize preinfusion risk factors associated with the development of each relapse pattern via a multicenter, retrospective review of children and young adults with r/r B-ALL treated with a murine-based CD19-CAR construct. Of 420 patients treated with CAR, 166 (39.5%) relapsed, including 83 (50%) CD19pos, 68 (41%) CD19neg, and 12 (7.2%) LS relapses. A greater cumulative number of prior complete remissions was associated with CD19pos relapses, whereas high preinfusion disease burden, prior blinatumomab nonresponse, older age, and 4-1BB CAR construct were associated with CD19neg relapses. The presence of a KMT2A rearrangement was the only preinfusion risk factor associated with LS. The median overall survival following a post-CAR relapse was 11.9 months (95% CI, 9-17) and was particularly dismal in patients experiencing an LS, with no long-term survivors following this pattern of relapse. Given the poor outcomes for those with post-CAR relapse, study of relapse prevention strategies, such as consolidative hematopoietic stem cell transplantation, is critical and warrants further investigation on prospective clinical trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lamble AJ, Myers RM, Taraseviciute A, et al. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023. PMID: 35482927. doi:10.1182/bloodadvances.2022007423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。